Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia

NCT03127644 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03127644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03127644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia
Lead sponsor
AstraZeneca
Phase
Phase 2/3
Overall status
Completed
Start date
June 14, 2017
Completion date
February 23, 2018
Enrollment
103 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia